Transcriptional effects of fingolimod treatment on peripheral T cells in relapsing remitting multiple sclerosis patients.
Giacomo SferruzzaFerdinando ClarelliElisabetta MasciaLaura FerrèLinda OttoboniMelissa SorosinaSilvia SantoroMassimo FilippiPaolo ProveroFederica EspositoPublished in: Pharmacogenomics (2022)
Aim: To investigate the transcriptional changes induced by Fingolimod (FTY) in T cells of relapsing remitting multiple sclerosis patients. Patients & methods: Transcriptomic changes after 6 months of FTY therapy were evaluated on T cells from 24 relapsing remitting multiple sclerosis patients through RNA-sequencing, followed by technical validation and pathway analysis. Results: Among differentially expressed genes, CX3CR1 and CCR7 resulted strongly up- and downregulated, respectively. Two relevant genes were validated with quantitative PCR and we largely confirmed findings from two previous microarray-based studies with similar design. Pathway analysis pointed to an involvement of processes related to immune function and cell migration. Conclusion: Our data support the evidence that FTY induces major transcriptional changes in genes involved in immune response and cell trafficking in T lymphocytes.
Keyphrases
- multiple sclerosis
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- immune response
- prognostic factors
- gene expression
- disease activity
- systemic lupus erythematosus
- cell migration
- rheumatoid arthritis
- bone marrow
- oxidative stress
- genome wide
- cell therapy
- mesenchymal stem cells
- mass spectrometry
- inflammatory response
- artificial intelligence
- chemotherapy induced